Petrichor Capital Partners
Petrichor Capital Partners is a venture capital firm launched in 2018, dedicated to supporting world-class healthcare managers and businesses. The firm provides structured investments to foster the development and commercial growth of innovative biopharmaceuticals, medical technologies, and services. With a deep in-house understanding of scientific, technical, and commercial expertise, Petrichor aims to identify and support the next generation of healthcare innovation, spanning from company formation to late-stage growth opportunities.
Petrichor Capital Partners
220 East 42nd Street, 37th / PH Floor, New York, NY 10017
What We Do
Petrichor Capital Partners provides structured investments to support the development and commercial growth of innovative biopharmaceuticals, medical technologies, and services.
The firm creates portfolio relationships beyond capital, helping private or public companies around the world achieve their growth potential.
Portfolio
Scion Life Sciences is dedicated to founding and building exceptional biotechnology companies that discover, develop, and seek to commercialize clinically transformational or curative new medicines.
#Biotechnology
Fennec Pharmaceuticals has received multiple investments from Petrichor, including a $45 million investment and a $20 million investment. The company has also announced FDA approval for PEDMARK® (Sodium Thiosulfate Injection).
#Pharmaceuticals
ITM has been involved in multiple collaborations and agreements, including a supply agreement for Actinium-225 and the opening of the world's largest Lutetium-177 production facility.
#Radiopharmaceuticals
Aurion Biotech has raised $120 million from various investors, including Petrichor, and has received breakthrough therapy designation for its drug candidate AURN001.
#Biotechnology